Status:
UNKNOWN
ctDNA Methylation for Detecting Ovarian Cancer
Lead Sponsor:
Lei Li
Conditions:
Epithelial Ovarian Cancer
Circulating Tumor DNA
Eligibility:
FEMALE
18+ years
Brief Summary
Ovarian cancer is one of the most dangerous and leading gynecological cancer, with significant cancer-related mortality among women. However, current detection methods are still limited, with approxim...
Detailed Description
This study has two phases: the "Clinical Performance Validation" cohort and the "Assay Accuracy Verification" cohort. The " Clinical Performance Validation" phase of this study will assess the reagen...
Eligibility Criteria
Inclusion Criteria:
- Patients ready for surgical treatment for pelvic mass or adnexal mass
- Age is greater than or equal to 18 years
- Not receiving any chemotherapy, physical therapy, or surgical treatment for ovarian lesions
- With ovarian pathology
- Willing to be tested and signed an informed consent form
- With available data of plasma CA125, Human epididymis protein 4 and effective imaging results
- The study will also enroll several patients with primary breast cancer, lung cancer, colon cancer, uterine cervical cancer and uterine carcinomas
Exclusion Criteria:
- Not meeting all the including criteria
- A sample of patients withdrawing from the trial
- Samples that the investigator believes should be excluded from this trial
Key Trial Info
Start Date :
March 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 24 2026
Estimated Enrollment :
1400 Patients enrolled
Trial Details
Trial ID
NCT05801276
Start Date
March 24 2023
End Date
March 24 2026
Last Update
April 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Li
Beijing, Beijing Municipality, China, 100730